Researchers Call for FDA to Require Negative Drug Studies on Product Labels After Approval of Drug with Mostly Negative Results
By
Cheryl Clark
Summary
Researchers argue that the FDA should require negative studies of new drugs to be included in product labeling, not just positive ones, to prevent misleading physicians and consumers about drug safety and efficacy. The analysis examines a drug that received FDA approval despite having more negative than positive studies, highlighting flaws in the current regulatory system that can lead to biased perceptions of a drug's true benefits and risks.
Source
bskyResearchers Call for FDA to Require Negative Drug Studies on Product Labels After Approval of Drug with Mostly Negative Resultsmedpagetoday.comKey quotes
· 2 pulledThe FDA should require negative studies of a new drug to be included in the product's labeling -- not just those studies with a beneficial finding -- to prevent physicians and consumers from being misled about the drug's safety and efficacy.
That's the conclusion of researchers who examined the nearly decades-long journey of rejections that led up to the FDA's
You might also wanna read
FDA's AI for Drug Approvals Found to Fabricate Studies
The FDA's AI system, designed to expedite drug approvals, has been discovered to generate fake studies and misrepresent research, raising co
The Onion·11mo ago
Clinical Trials Exclude High-Risk Patients, Underestimating Drug Harms
This research paper examines how clinical trials systematically exclude high-risk patients, leading to underestimation of drug harms and sid
nber.org·6mo ago
FDA Announces Plans to Restrict Non-Approved GLP-1 Drugs in Compounded Medications
The FDA is announcing its intent to take action against non-FDA-approved GLP-1 drugs, specifically targeting GLP-1 active pharmaceutical ing
fda.gov·4mo ago
The costly failure of amyloid-beta drugs: A cautionary tale in pharmaceutical development
The article discusses drug classes that are perceived as failures after massive investment and clinical trials, using amyloid-beta drugs for
owlposting.com·1mo ago
Opinion: Statin Use May Pose Greater Diabetes Risk Than FDA Acknowledges
This opinion piece argues that the widespread use of statins for cholesterol reduction may lead to a significant increase in Type 2 diabetes
nytimes.com·7d ago
NIH Halts Tuberculosis Research Over Unfounded 'Dangerous' Gain-of-Function Concerns
A UC Berkeley professor and NIH grant recipient describes how the NIH abruptly ordered them to stop their tuberculosis research, deeming it
statnews.com·8mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.